Abstract:OBJECTIVES:This prospective, randomized, open-label study aimed to compare the effects of antihypertensive treatment based on amlodipine or hydrochlorothiazide on the circulating microparticles and central blood pressure values of hypertensive patients.METHODS:The effects of treatments on circulating microparticles were assessed during monotherapy and after the consecutive addition of valsartan and rosuvastatin followed by the withdrawal of rosuvastatin. Each treatment period lasted for 30 days. Central blood … Show more
“…An increase in PMP was observed in the amlodipine group after discontinuation of rosuvastatin. 93 This study suggests an impact of concomitant therapies on microparticles.…”
Section: Microparticles and Therapeutic Interventionsmentioning
Microparticles are small cell vesicles that are derived from the cell membrane in response to different biological processes. There is growing evidence supporting the association between microparticles and cardiovascular disease, as their pathophysiology commonly includes endothelial damage and chronic inflammation which also promote a prothrombotic state. The direct causal link between the release of the different subtypes of microparticles and their implications on physiological and pathological conditions is still not completely elucidated. However, evidence suggests microparticles released from platelets, leukocytes, and endothelium may help to evaluate vascular health as they have a relevant role in inflammation, endothelial function, and thrombosis. This review aims to provide a short overview of the biogenesis, characteristics, and detection methodology of microparticles with a special focus on their possible implication in cardiovascular settings.
“…An increase in PMP was observed in the amlodipine group after discontinuation of rosuvastatin. 93 This study suggests an impact of concomitant therapies on microparticles.…”
Section: Microparticles and Therapeutic Interventionsmentioning
Microparticles are small cell vesicles that are derived from the cell membrane in response to different biological processes. There is growing evidence supporting the association between microparticles and cardiovascular disease, as their pathophysiology commonly includes endothelial damage and chronic inflammation which also promote a prothrombotic state. The direct causal link between the release of the different subtypes of microparticles and their implications on physiological and pathological conditions is still not completely elucidated. However, evidence suggests microparticles released from platelets, leukocytes, and endothelium may help to evaluate vascular health as they have a relevant role in inflammation, endothelial function, and thrombosis. This review aims to provide a short overview of the biogenesis, characteristics, and detection methodology of microparticles with a special focus on their possible implication in cardiovascular settings.
“…In contrast, patients in whom the antihypertensive medication was up-titrated showed a decrease in BP levels along with lower levels of EVs. It is important to consider that in addition to decreasing BP levels, different antihypertensive medications have shown to have some pleiotropic effects including enhancement of nitric oxide activity, improvement of endothelial function, lowering of platelet activation, improvement of fibrinolytic balance and alleviation of the prothrombotic state [8,[36][37][38]. From our observations, it appears that changes in BP, irrespective of how these were achieved, are most closely associated with changes in EVs.…”
Section: Discussionmentioning
confidence: 94%
“…The use of specific antihypertensive drug classes has also been demonstrated to have an effect on EV formation [36–38,49]. Our sample size was probably not powerful enough to evaluate the impact of individual antihypertensive medications, as patients were commonly treated with dual or triple therapy, and we cannot evaluate the effect of each class separately.…”
Introduction: Elevated nocturnal blood pressure (BP) is closely associated with increased risk of cardiovascular (CV) events. Circulating extracellular vesicles (EVs) have been proposed as a potential CV risk biomarker and shown to correlate with BP. The present study aimed to assess whether a reduction in BP is paralleled by respective changes in EVs.Methods: Fifty-five hypertensive patients (age: 57.7 AE 14.1 years) were included in the study. EVs and BP were assessed at baseline and at 12 weeks follow-up. Interventions to lower BP included advice on life-style modification only or life-style advice combined with additional pharmacotherapy. EVs were evaluated by flow cytometry (CD41R/Annexin VR) and BP by unobserved automated office BP and ambulatory BP monitoring.Results: Nocturnal systolic BP correlated with EV levels at baseline (P ¼ 0.01). Multivariable regression models showed that changes in nocturnal systolic BP (adjusted R 2 ¼ 0.23; P ¼ 0.01) and diastolic BP (adjusted R 2 ¼ 0.18; P ¼ 0.02) were associated with respective changes in EV levels. Furthermore, intervention-induced improvement of systolic dipping was associated with a reduction in EVs in the univariate analysis (adjusted R 2 ¼ 0.06; P ¼ 0.03). In contrast, systolic office, 24 h-and daytime-BP did not show significant associations with EVs. Patients whose medication was up-titrated at baseline showed a trend towards lower EV levels at follow-up (absolute change of À1.7 AE 1.3 EV/ml; P ¼ 0.057) Conclusions: Circulating platelet-derived EVs were positively associated with nocturnal BP and therapyinduced changes over a 12-week treatment period. EVs may provide an integrated measure of BP changes achieved with pharmacotherapy.
“…Circulating endothelium-, monocyte- and platelet-derived microparticles were determined as previously reported [ [23] , [24] , [25] ]. See Supplemental Methods for details.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.